J98.8 Other specified respiratory disorders
The ICD-10-CM code for Other specified respiratory disorders is J98.8 (FY2026). It is a billable, claim-ready diagnosis code.
Classification
- Section
- J96-J99: Other diseases of the respiratory system (J96-J99)
- Category J98
- 16 codes (12 billable)
- FY2026 Status
- Stable since FY2024
Also Known As
ICD-10-CM Alphabetic Index entries that lead to J98.8:
- Obstruction, obstructed, obstructive › airway
- Decompensation › respiratory
- Infection, infected, infective (opportunistic) › respiratory (tract) NEC
- Inflammation, inflamed, inflammatory (with exudation) › chest
- Pneumatocele (lung) › tension
- Obstruction, obstructed, obstructive › respiratory
- Infection, infected, infective (opportunistic) › respiratory (tract) NEC › chronic
- Infection, infected, infective (opportunistic) › virus, viral NOS › chest
U.S. Hospital Utilization
- An estimated 12,360 U.S. inpatient stays in 2023 included J98.8 among the documented diagnoses.
- 1,225 stays listed it as the principal diagnosis.
Source: National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, 2016–2023. National survey-weighted estimates.
Official Coding Guidelines
Respiratory infection NOS—assign U07.1 + J98.8If the COVID-19 is documented as being associated with a respiratory infection, NOS, codes U07.1 and J98.8, Other specified respiratory disorders, should be assigned.
COPD/asthma: acute exacerbation vs uncomplicateda. Chronic Obstructive Pulmonary Disease [COPD] and Asthma 1) Acute exacerbation of chronic obstructive bronchitis and asthma The codes in categories J44 and J45 distinguish between uncomplicated cases and those in acute exacerbation. An acute exacerbation is a worsening or a decompensation of a chronic condition. An acute exacerbation is not equivalent to an infection superimposed on a chronic condition, though an exacerbation may be triggered by an infection.
Source: CMS — ICD-10-CM Official Guidelines for Coding and Reporting, FY2026